ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VNDA vs EVMN // 10Y YIELD & FRED MACRO BETA

Vanda Pharmaceuticals Inc. (NASDAQ) VS. Evommune Inc. (NYSE) • 15-METRIC TALLY: VNDA 1 — EVMN 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VNDA VS. EVMN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VNDA EVMN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 8.70% 85.70% -77.00 EVMN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.87 -5.67 EVMN /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 VNDA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 26.7 49.5 -22.82 EVMN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $244.9M $247.1M -$2.3M EVMN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VNDA REV EVMN REV VNDA GROSS % EVMN GROSS % VNDA FCF EVMN FCF
FY 2025 $216.1M $13.0M — — -$110.4M -$76.7M
FY 2024 $198.8M $7.0M — — -$16.2M -$58.3M
FY 2023 $192.6M — — — $12.8M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VNDA // BETA —
EVMN // BETA —